Incidence, risk factors and outcome of acute kidney injury (AKI) in patients with COVID-19.
AKI
COVID-19
Dialysis
Mortality
Risk factors
Urine
Journal
Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
07
12
2020
accepted:
07
06
2021
pubmed:
2
7
2021
medline:
30
9
2021
entrez:
1
7
2021
Statut:
ppublish
Résumé
Acute kidney injury (AKI) is a severe complication of coronavirus disease-2019 (COVID-19). This study aims to evaluate incidence, risk factors and case-fatality rate of AKI in patients with COVID-19. We reviewed the health medical records of 307 consecutive patients with COVID-19 hospitalized at the University Hospital of Modena, Italy. AKI was diagnosed in 69 out of 307 (22.4%) COVID-19 patients. Stages 1, 2, or 3 AKI accounted for 57.9%, 24.6% and 17.3%, respectively. AKI patients had a mean age of 74.7 ± 9.9 years. These patients showed higher serum levels of the main markers of inflammation and higher rate of severe pneumonia than non-AKI patients. Kidney injury was associated with a higher rate of urinary abnormalities including proteinuria (0.44 ± 0.85 vs 0.18 ± 0.29 mg/mg; P = < 0.0001) and microscopic hematuria (P = 0.032) compared to non-AKI patients. Hemodialysis was performed in 7.2% of the subjects and 33.3% of the survivors did not recover kidney function after AKI. Risk factors for kidney injury were age, male sex, CKD and higher non-renal SOFA score. Patients with AKI had a mortality rate of 56.5%. Adjusted Cox regression analysis revealed that COVID-19-associated AKI was independently associated with in-hospital death (hazard ratio [HR] = 4.82; CI 95%, 1.36-17.08) compared to non-AKI patients. AKI was a common and harmful consequence of COVID-19. It manifested with urinary abnormalities (proteinuria, microscopic hematuria) and conferred an increased risk for death. Given the well-known short-term sequelae of AKI, prevention of kidney injury is imperative in this vulnerable cohort of patients.
Sections du résumé
BACKGROUND
BACKGROUND
Acute kidney injury (AKI) is a severe complication of coronavirus disease-2019 (COVID-19). This study aims to evaluate incidence, risk factors and case-fatality rate of AKI in patients with COVID-19.
METHODS
METHODS
We reviewed the health medical records of 307 consecutive patients with COVID-19 hospitalized at the University Hospital of Modena, Italy.
RESULTS
RESULTS
AKI was diagnosed in 69 out of 307 (22.4%) COVID-19 patients. Stages 1, 2, or 3 AKI accounted for 57.9%, 24.6% and 17.3%, respectively. AKI patients had a mean age of 74.7 ± 9.9 years. These patients showed higher serum levels of the main markers of inflammation and higher rate of severe pneumonia than non-AKI patients. Kidney injury was associated with a higher rate of urinary abnormalities including proteinuria (0.44 ± 0.85 vs 0.18 ± 0.29 mg/mg; P = < 0.0001) and microscopic hematuria (P = 0.032) compared to non-AKI patients. Hemodialysis was performed in 7.2% of the subjects and 33.3% of the survivors did not recover kidney function after AKI. Risk factors for kidney injury were age, male sex, CKD and higher non-renal SOFA score. Patients with AKI had a mortality rate of 56.5%. Adjusted Cox regression analysis revealed that COVID-19-associated AKI was independently associated with in-hospital death (hazard ratio [HR] = 4.82; CI 95%, 1.36-17.08) compared to non-AKI patients.
CONCLUSION
CONCLUSIONS
AKI was a common and harmful consequence of COVID-19. It manifested with urinary abnormalities (proteinuria, microscopic hematuria) and conferred an increased risk for death. Given the well-known short-term sequelae of AKI, prevention of kidney injury is imperative in this vulnerable cohort of patients.
Identifiants
pubmed: 34196877
doi: 10.1007/s10157-021-02092-x
pii: 10.1007/s10157-021-02092-x
pmc: PMC8245663
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1203-1214Informations de copyright
© 2021. Japanese Society of Nephrology.
Références
Lancet. 2020 Dec 12;396(10266):1881-1882
pubmed: 33308465
Clin Kidney J. 2020 Jun 06;13(3):354-361
pubmed: 32695326
JAMA. 2017 Jan 17;317(3):290-300
pubmed: 28114553
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Adv Chronic Kidney Dis. 2018 Mar;25(2):166-180
pubmed: 29580581
Clin J Am Soc Nephrol. 2020 Oct 7;15(10):1394-1402
pubmed: 32963018
Int Urol Nephrol. 2020 Oct;52(10):1911-1914
pubmed: 32661623
Swiss Med Wkly. 2021 Mar 01;151:w20482
pubmed: 33706383
Clin J Am Soc Nephrol. 2020 Dec 31;16(1):14-25
pubmed: 33199414
Lancet. 2020 Aug 29;396(10251):597-598
pubmed: 32818439
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
Curr Probl Cardiol. 2020 Aug;45(8):100618
pubmed: 32439197
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Am J Kidney Dis. 2015 Oct;66(4):602-12
pubmed: 25975964
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Ren Fail. 2020 Nov;42(1):638-645
pubmed: 32660294
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
Expert Opin Drug Saf. 2014 Jan;13(1):57-65
pubmed: 24073682
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Clin Kidney J. 2021 Jan 24;14(Suppl 1):i30-i39
pubmed: 33796284
Lancet Infect Dis. 2020 Jul;20(7):773
pubmed: 32171390
Cytometry A. 2020 Apr;97(4):340-343
pubmed: 32187834
J Am Soc Nephrol. 2021 Jan;32(1):151-160
pubmed: 32883700
J Am Soc Nephrol. 2020 Sep;31(9):1959-1968
pubmed: 32680910
J Crit Care. 2020 Dec;60:13-22
pubmed: 32731101
J Am Soc Nephrol. 2020 Jun;31(6):1157-1165
pubmed: 32345702
BMC Anesthesiol. 2020 Jun 3;20(1):140
pubmed: 32493268
Burns. 2010 Mar;36(2):205-11
pubmed: 19836141
Am J Kidney Dis. 2010 Apr;55(4):622-7
pubmed: 20338463
JAMA Netw Open. 2021 Mar 1;4(3):e211095
pubmed: 33688965
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
Geroscience. 2018 Apr;40(2):201-217
pubmed: 29488059
Blood Purif. 2021;50(2):263-267
pubmed: 32344395
Crit Care. 2013 Jan 24;17(1):R14
pubmed: 23347825
Kidney Int. 2020 Jul;98(1):219-227
pubmed: 32327202
J Am Soc Nephrol. 2005 Nov;16(11):3365-70
pubmed: 16177006
Nat Rev Immunol. 2020 May;20(5):269-270
pubmed: 32273594
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Am Soc Nephrol. 2020 Sep;31(9):2145-2157
pubmed: 32669322
Semin Nephrol. 2016 Jul;36(4):283-92
pubmed: 27475659
Kidney Int Rep. 2020 Oct;5(10):1815-1822
pubmed: 32838081
Front Pediatr. 2020 Jan 24;7:517
pubmed: 32039104
Kidney Int. 2020 Jul;98(1):209-218
pubmed: 32416116
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Kidney Int Rep. 2020 May 17;5(7):1100-1105
pubmed: 32426558
Kidney Int. 2008 Jul;74(1):101-7
pubmed: 18385668